Background: Partnered status is an independent predictor of clinical outcomes, including overall survival, among patients with cancer. However, the mechanisms by which partnered status impacts survival are not fully understood and to the authors' knowledge the associations between partnered status and the specific attributes of chemotherapy have not been studied to date.
Methods: The current study was an observational study of patients with resected American Joint Committee on Cancer (AJCC) stage III colon cancer diagnosed from 2008 through 2015 and recruited from an academic cancer center and 2 large community oncology practices. Outcome measures were specific attributes of adjuvant chemotherapy. Partnered status (partnered vs unpartnered) was the primary independent variable. Bivariate comparisons between independent variables and the primary outcomes were performed. Associations between partnered status and the outcomes also were analyzed using multivariable generalized estimating equations using a logit link.
Results: Data were collected from 436 patients. Of these patients, approximately 65% were from community oncology practices. Approximately 62% were partnered (married or living with a partner), and approximately 86% received adjuvant chemotherapy. Among these individuals, 87% received multiagent chemotherapy and 65% completed 6 months of therapy. Partnered patients were found to have a higher odds of completing chemotherapy (odds ratio, 1.98; 95% CI, 1.04-3.77).
Conclusions: In this innovative investigation of the associations between partnered status and specific attributes of curative-intent chemotherapy, approximately 35% of patients terminated chemotherapy early. Having a partner increased the odds of completing therapy, which may be one mechanism through which having a partner improves disease-specific outcomes among patients with colon cancer. Identifying those aspects of partner support that can be reproduced with community or clinical personnel may help unpartnered patients to complete the recommended course of curative-intent chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856404 | PMC |
| http://dx.doi.org/10.1002/cncr.32459 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Heritable Symbionts in Parisian Bedbugs (Hemiptera: Cimicidae).
Environ Microbiol Rep
February 2025
Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Like many insects, the biology of bedbugs is impacted by a range of partner heritable microbes. Three maternally inherited symbionts are recognised: Wolbachia (an obligate partner), Symbiopectobacterium purcellii strain SyClec, and Candidatus Tisiphia sp. (facultative symbionts typically present in some but not all individuals).
View Article and Find Full Text PDFHIV risk perception and PrEP uptake among pregnant women offered PrEP during antenatal care in Kenya.
J Acquir Immune Defic Syndr
January 2025
University of Washington Department of Global Health, Seattle, Washington, USA.
Background: Self-perceived HIV risk influences PrEP use, though few data on risk perception are available among pregnant women. We evaluated HIV risk perception and PrEP uptake among pregnant women in Kenya.
Methods: We utilized data from a randomized trial evaluating universal versus risk-based PrEP delivery models at 20 antenatal clinics in Kenya (NCT03070600).
Clinical exome sequencing for carrier screening in assisted reproductive technology and sperm donation.
J Assist Reprod Genet
January 2025
Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an, China.
Purpose: To assess the efficacy of clinical exome sequencing (CES) in individuals involved in assisted reproductive technology (ART) or sperm donor programs, with a specific focus on its impact on clinical decision-making.
Methods: A total of 3991 individuals without a family history of genetic disorders underwent CES targeting 5595 genes at a reproductive center between December 2022 and April 2024. The cohort comprised 217 sperm donors, 232 female recipients, and 1771 couples (3542 patients) undergoing ART with their own gametes.
Strategies for recruitment and retention of diverse and underserved cancer survivor and caregiver dyads in clinical trials.
Contemp Clin Trials Commun
April 2025
University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, AZ, USA.
Background: Cancer survivor-caregiver dyads from underrepresented racial and ethnic groups and those with lower socioeconomic status are less likely to participate in clinical research. Sociocultural and socioeconomic barriers perpetuate health inequity and increase disparities in cancer care.
Purpose: We describe our systematic approach to recruiting and retaining diverse survivor-caregiver dyads in supportive cancer care studies.
Emotional ecosystems: Understanding the relationship between family interactions and anxiety among cancer caregivers.
Palliat Support Care
January 2025
Washington University in St. Louis School of Medicine, Saint Louis, MO, USA.
Objectives: Recent studies have challenged the assumption that families are invariable sources of support for cancer caregivers, noting that relationships with family members can have both positive and negative effects on caregiver well-being. This study expands upon prior literature to examine the relationship between cancer caregivers' perceptions of the quality of their family interactions and their symptoms of anxiety.
Methods: We employed secondary analysis of baseline data from a multisite randomized clinical trial of an intervention for cancer caregivers conducted at 3 large academic palliative care clinics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!